PRPO
What one share of Precipio holds
Laboratory Analytical Instruments
We are a healthcare biotechnology company with a mission to battle the systemic problem of disease misdiagnosis, by focusing on improving cancer diagnostics, particularly, hematologic malignancies. Our objective is to enhance diagnostic accuracy and accessibility while building a sustainable business model that supports ongoing innovation.
Precipio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $15.60 |
|---|---|
| Profit | −$0.70 |
| Capex (buildings and equipment) | $0.18 |
| Free cash flow | $0.45 |
| Cash and investments | $1.72 |
| Debt | $0.65 |
| Book value | $8.25 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $111.42 | −$2,147 | $9.25 | −$441.86 | — | — |
| 2018 | $39.75 | −$276.40 | $1.35 | −$95.08 | — | $53.27 |
| 2019 | $10.98 | −$46.51 | $0.19 | −$32.29 | — | $33.44 |
| 2020 | $7.39 | −$16.96 | $0.18 | −$9.21 | — | $16.08 |
| 2021 | $8.39 | −$8.07 | $0.65 | −$6.88 | — | $21.63 |
| 2022 | $8.27 | −$10.73 | $0.24 | −$7.03 | — | $14.29 |
| 2023 | $11.71 | −$4.51 | $0.10 | −$2.84 | — | $10.16 |
| 2024 | $12.65 | −$2.93 | $0.15 | $0.15 | — | $8.10 |
| 2025 | $14.98 | −$0.23 | $0.20 | $0.22 | — | $8.18 |